A5082085036- Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cutaneous lymphoproliferative disorders research
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- T-cell and Retrovirus Studies
- Erythrocyte Function and Pathophysiology
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Blood groups and transfusion
- Radiomics and Machine Learning in Medical Imaging
- Multiple Myeloma Research and Treatments
- Ovarian cancer diagnosis and treatment
- Nail Diseases and Treatments
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- COVID-19 and healthcare impacts
- Neutropenia and Cancer Infections
- Hemoglobinopathies and Related Disorders
- Multiple and Secondary Primary Cancers
- Hematopoietic Stem Cell Transplantation
- Parvovirus B19 Infection Studies
- Atrial Fibrillation Management and Outcomes
Princess Alexandra Hospital
2017-2025
The University of Queensland
2019-2025
Princess Alexandra Hospital
2018-2023
Translational Research Institute
2023
Spinal Cord Injury BC
2019
BC Cancer Agency
2014-2016
Monash Health
2014-2015
University of British Columbia
2015
Monash University
2015
The Alfred Hospital
2012-2013
Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured R-CHOP. Polatuzumab vedotin an antibody-drug conjugate targeting CD79b, which ubiquitously expressed on the surface malignant B cells.We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate modified regimen R-CHOP (pola-R-CHP), in vincristine was replaced polatuzumab vedotin, as...
PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There no consensus regarding the optimal approach to prophylaxis. This study was designed determine whether high-dose methotrexate (HD-MTX) effective at preventing in patients high risk this complication. PATIENTS AND METHODS Patients age 18-80 years with lymphoma and progression, treated curative-intent anti–CD20-based chemoimmunotherapy, were included international, retrospective,...
Dabigatran is an oral direct thrombin inhibitor that does not require routine laboratory monitoring. However, assessment of its anticoagulant effect in certain clinical settings desirable. We examined the relationship between dabigatran levels, as determined by Hemoclot assay (HTI), time (TT) and activated partial thromboplastin (aPTT) using different reagents. describe these parameters with outcomes patients receiving dabigatran. Seventy-five plasma samples from 47 were analysed. The HTI...
Studies in classical Hodgkin lymphoma (cHL) typically measure the time to events from diagnosis. We evaluated risk of relapse at event-free survival points cHL and compared death expected mortality rates British Columbia (BC).The BC Cancer Agency Lymphoid Database was screened identify all patients age 16 69 years diagnosed with between 1989 2012 treated chemotherapy regimen doxorubicin, bleomycin, vinblastine, dacarbazine (or equivalent). observed general population using age-, sex-,...
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare form of T-cell that occurs after implantation breast prostheses. We performed comprehensive next generation sequencing based genomic characterization 11 cases BIA-ALCL including sequence variant detection on 180 genes frequently mutated in haematological malignancy, genome-wide copy number assessment, structural involving the receptor loci and TRB deep-sequencing. observed variants leading to JAK/STAT activation 10...
Abstract The COVID‐19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known cause disproportionately severe disease in cancer, and lymphoma, myeloma chronic lymphocytic leukaemia are likely be at particular risk related COVID‐19. This statement has been developed by consensus among authors from Australia New Zealand. We aim provide supportive guidance clinicians making individual patient decisions during pandemic, periods that...
Tumour 'bulk' has historically been considered an important prognostic marker and clinical tool to guide treatment in patients with lymphoma. However, its use definitions trial designs varies significantly it is unclear how this influenced the relevance of bulk contemporary practice. This comprehensive literature review evaluated definitions, applications impact phase 3 randomised trials four major lymphoma subtypes. Overall, 87 studies were identified across follicular (FL), diffuse large...
ABSTRACT Background The TROG 99.03 trial demonstrated improved progression‐free survival for patients with early‐stage follicular lymphoma (FL) treated systemic therapy using rituximab‐cyclophosphamide, vincristine, prednisolone (R‐CVP) after involved‐field radiotherapy (RT) versus RT. As was associated more acute toxicity, the possibility of long‐term and no benefit yet, cost‐effectiveness RT+R‐CVP is important. Aim We performed a analysis RT (reference), RT+CVP, from trial. Methods...
Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare CD30+ lymphoproliferative disorder with excellent outcomes reported despite frequent relapses. Limited information exists on the development of systemic lymphoma. The British Columbia Cancer Agency (BCCA) Lymphoid Database was searched to identify all adults diagnosed PCALCL from 1993 2013. From 2005, BCCA endorsed radiotherapy (RT) alone for limited stage data failing support chemotherapy. Forty-seven patients were...
Management practices in early-stage (I/II) follicular lymphoma (FL) are variable and include radiation (RT), systemic therapy, or combined modality therapy (CMT). There is a paucity of data regarding maintenance rituximab this cohort. We conducted an international retrospective study patients with newly diagnosed FL staged positron emission tomography (PET)-computed bone marrow biopsy. Three hundred sixty-five (stage I, n = 221), median age 63 years, treated from 2005-2017 were included,...
Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder [PTLD]) is a highly aggressive non-Hodgkin lymphoma. It typically treated with high-dose methotrexate-based regimens. Outcomes are dismal and clinical trials lacking. almost always Epstein–Barr virus (EBV) associated. Two patients (CA1-2) presented EBV-associated PCNSL after renal transplant. CA1 was on hemodialysis had prior disseminated cryptococcus...
Australia and New Zealand have achieved excellent community control of COVID‐19 infection. In light the imminent vaccination roll out in both countries, representatives from Haematology Society infectious diseases specialists collaborated on this consensus position statement regarding patients with haematological disorders. It is our recommendation that malignancies, some benign disorders, should expedited access to high‐efficacy vaccines, given these are at high risk morbidity mortality...
Summary Grade 3B follicular lymphoma (G3BFL) is a rare thought to sit on continuum between low‐grade FL and diffuse large B‐cell (DLBCL). The prognostic impact of quantitative positron emission tomography (PET) metrics such as total metabolic tumour volume (TMTV), lesion glycolysis (TLG), maximum standard uptake value (SUVmax) have been extensively analysed in DLBCL, but G3BFL data are lacking. Here, we describe PET outcomes radiomic characteristics 46 cases uniformly treated with R‐CHOP...
In T-cell lymphoma, malignant T cells arising from a founding clone share an identical cell receptor (TCR) and can be identified by the over-representation of this TCR relative to TCRs patient's repertoire normal cells. Here, we demonstrate that information extracted RNA-seq data provide higher resolution view peripheral lymphomas (PTCLs) than provided conventional methods.For 60 subjects with PTCL, flow cytometry/FACS was used identify sort aberrant populations diagnostic lymph node...
Grade (G) 3B follicular lymphoma (FL) is a rare FL subtype which exists on histological continuum between 'lowgrade' (Grade 1, 2 and 3A FL) diffuse large B-cell (DLBCL) appearing to share features with each. Clinical characteristics outcomes are poorly understood due lack of adequate representation in prospective trials large-scale analyses. We analyzed 157 G3BFL cases from 18 international centers, two comparator groups; G3AFL (n=302) DLBCL (n=548). Composite histology or low-grade occurred...
We report a case of 75-year-old male with indolent chronic lymphocytic leukaemia (CLL) for 8 years, who presented 6-month history painful, zosteriform eruption in T3-4 distribution that evolved into an unusual crop papular nodules. Upon biopsy and immunostaining these lesions CLL was proven consistent cutis related to varicella-zoster virus reactivation. In the absence other treatment indices, he commenced on chlorambucil successful resolution both his pain lesions.